Progression Free Survival Outcomes

Faculty present the progression-free survival findings from CABINET across both cohorts, emphasizing the encouraging and practice-changing results in a heavily pretreated population. In the pancreatic neuroendocrine tumor cohort, median progression-free survival exceeded 13 months with cabozantinib versus roughly 4 months with placebo. In the extra-pancreatic cohort, progression-free survival surpassed 8 months versus approximately 4 months with placebo. The panel underscores the trial's inclusion of lung neuroendocrine tumors, a population historically excluded from clinical trials, and notes that nearly all lung patients had already received everolimus. Faculty discuss the extrapolated lung subgroup data, citing an impressive hazard ratio in this pretreated population, and caution against assuming the extra-pancreatic cohort is predominantly small bowel, given its composition included substantial lung and thymic representation. The discussion frames these results as meaningful evidence supporting cabozantinib activity across diverse neuroendocrine tumor subtypes and reinforces the value of inclusive trial design.